Skip to main content
VITRAFY LIFE SCIENCES LIMITED logo

VITRAFY LIFE SCIENCES LIMITED — Investor Relations & Filings

Ticker · VFY ISIN · AU0000361297 ASX Professional, scientific and technical activities
Open in API
Filings indexed 91 across all filing types
Latest filing 2025-03-19 Investor Presentation
Country AU Australia
Listing ASX VFY

About VITRAFY LIFE SCIENCES LIMITED

https://www.vitrafy.com

Vitrafy Life Sciences Limited specializes in the development and commercialization of advanced cryopreservation technologies designed to optimize the preservation and transport of biological materials. The company provides end-to-end cold chain solutions, focusing on maintaining the viability and functionality of sensitive life science products, including cells, tissues, and organs. Its core technology utilizes precise, automated cooling and warming protocols to minimize cellular damage during the freezing process, addressing critical challenges in regenerative medicine, cell and gene therapy, and biobanking. By integrating hardware, software, and specialized consumables, Vitrafy aims to standardize cryopreservation workflows and improve clinical outcomes through enhanced sample recovery and data-driven monitoring throughout the supply chain.

Recent filings

Filing Released Lang Actions
NWR Virtual Healthcare Conference Presentation 32 pages 2.1MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated 20 March 2025, presenting a detailed investor presentation delivered at the NWR Virtual Healthcare Conference. It includes company overview, business strategy, market opportunity, and product information. The text explicitly states it is a presentation by the Deputy CEO and Executive Director. There is no indication of full financial statements or detailed quarterly or annual financial results. The document is lengthy (15,000 characters) and contains detailed presentation content rather than a brief announcement or a certification. Therefore, it fits the category of an Investor Presentation (IP).
2025-03-19 English
Change of Director's Interest Notice 3 pages 286.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares held before and after the change, the nature of the interest, and the date of change. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial performance data, management discussion, or regulatory certifications. The document length is 4442 characters, which is consistent with a detailed director's dealing notice. Therefore, the appropriate classification is Director's Dealing (DIRS).
2025-03-18 English
Vitrafy to present at NWR Virtual Healthcare Conference 1
Investor Presentation Classification · 85% confidence The document is an ASX announcement dated 19 March 2025, stating that Vitrafy Life Sciences Limited will present at the NWR Virtual Healthcare Conference on 20 March 2025. It invites shareholders and investors to attend the presentation and provides links for registration and replay. There is no financial data, no detailed report, no voting results, no management changes, no legal updates, or other regulatory filings. The document is essentially an announcement of an upcoming investor presentation event, not the presentation itself or a report. Therefore, the most appropriate classification is Investor Presentation (IP) as it relates to a presentation for investors focusing on company information and strategy, even though the actual presentation is to occur later and this is an announcement of it. Given the content, confidence is high but not absolute since the presentation is upcoming and this is an announcement, but the category best fits the nature of the document.
2025-03-18 English
Vitrafy Awarded Industry Growth Program Grant 2 pages 137.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 18 March 2025 about Vitrafy Life Sciences Limited being awarded a $4.8 million Industry Growth Program Grant. It details the grant purpose, terms of the agreement, and includes quotes from company executives. There are no financial statements, no detailed financial performance data, no regulatory certifications, or voting results. The document is relatively short (3782 characters) and serves as an announcement of a grant funding event, which is a capital/financing update. It is not a report, transcript, or regulatory filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-03-17 English
Notification of cessation of securities - VFY 4 pages 14.9KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of certain securities (options) for VITRAFY LIFE SCIENCES LIMITED. It provides specific information about securities that have ceased, reasons for cessation, and updated issued capital figures. The document is a regulatory announcement related to changes in the company's issued capital, specifically the cessation of securities, rather than a financial report or management discussion. It fits the category of Share Issue/Capital Change announcements, which cover new share issues, stock splits, or other capital changes including cessation or lapse of securities.
2025-02-27 English
Application for quotation of securities - VFY 5 pages 16.7KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) form used for the application for quotation of securities. It details the release of restricted securities from escrow and the subsequent quotation of these securities on the ASX. The document includes specifics about the number of securities, their class, and the fact that these securities are being quoted following the expiry of escrow restrictions. There is no financial report, earnings data, or management discussion present. This is a regulatory announcement related to capital structure changes, specifically the quotation of securities after escrow expiry. According to the filing definitions, announcements related to new share issues, stock splits, or other capital changes fall under Share Issue/Capital Change (SHA). Therefore, this document should be classified as SHA.
2025-02-20 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.